Xoma | XOMA - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Agenus USD 186.46M 40.34M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Ardelyx USD 504.51M 2.9M 2026-03
aTyr Pharma USD 79.65M 435.68M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Celldex Therapeutics USD 511.25M 71.73M 2026-03
Curis USD 19.97M 9.27M 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Incyte USD 7.34B 381.14M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 207.62B 542M 2026-03
Prothena USD 349.89M 23.09M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Xoma USD 263.15M 39.7M 2025-09